Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis


Amirhossein Sahebkar | Maria-Corina Serban | Dimitri P. Mikhailidis | Peter P. Toth | Paul Muntner | Sorin Ursoniu | Svetlana Mosterou | Stephen Glasser | Seth S. Martin | Steven R. Jones | Manfredi Rizzo | Jacek Rysz | Allan D. Sniderman | Michael J. Pencina | Maciej Banach | Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group

First published: 3 December 2015| https://doi.org/10.1016/j.phrs.2015.12.001



Several studies suggest differences between fibrates and statins in lowering plasma fibrinogen (Fib) concentrations, but the evidence is not definitive. Therefore, the aim of this meta-analysis of head-to-head randomized trials was to compare the efficacy of statins and fibrates on plasma Fib concentrations.


The literature search included Medline, Scopus, and Web of Science up to February 1st, 2015, to identify head-to-head comparative randomized trials investigating the efficacy of fibrates vs statins on plasma Fib concentrations.


In total 22 trials with 2762 participants were included to the meta-analysis. Random-effect meta-analysis suggested a significantly greater effect of fibrates vs statins in lowering plasma Fib concentrations (weighted mean difference [WMD]: −40.7 mg/dL, 95% confidence interval [CI]: −55.2, −26.3, p < 0.001). When the analysis was stratified according to the type of fibrate administered, there were significant Fib-lowering effects with both bezafibrate (n = 8 treatment arms; WMD: −23.7 mg/dL, 95% CI: −41.8, −5.7, p = 0.01) and fenofibrate (n = 15 treatment arms; WMD: −43.7 mg/dL, 95% CI: −61.3, −26.2, p < 0.001). Overall, there was a numerically greater effect in the subgroup of trials with ≥12 weeks duration (n = 17 treatment arms; WMD: −42.7 mg/dL, 95% CI: −60.3, −25.1, p < 0.001) compared with the subgroup of trials lasting <12 weeks (n = 7 treatment arms; WMD: −36.7 mg/dL, 95% CI: −52.0, −21.4, p < 0.001).


Monotherapy with either fibrates or statins suggested a significantly greater effect of fibrates in lowering plasma Fib concentrations. According to these findings, mechanisms associated with fibrinogen metabolism might be responsible for the distinct effects of statins and fibrates in reducing cardiovascular endpoints.

  1. A. Sahebkar et al.
    Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials
  2. N.B. Adams et al.
    Statin therapy and levels of hemostatic factors in a healthy population: the multi-ethnic study of atherosclerosis
    J. Thromb. Haemost.
  3. M. Banach et al.
    Lipids, blood pressure and kidney update 2014
    Pharmacol. Res.
  4. R.N.A. Black et al.
    The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial
    J. Diabetes Complications
  5. M.H. Davidson et al.
    Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study
    Clin. Ther.
  6. A. Saklamaz et al.
    The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: A comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type iia and type iib hyperlipidemia
  7. J.-C. Ansquer et al.
    Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: a 12-week, multicenter, randomized, open-label, parallel-group study
    Curr. Ther. Res.
  8. R.J. Frost et al.
    Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia
    Am. J. Cardiol.
  9. K.K. Koh et al.
    Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia
    J. Am. Coll. Cardiol.
  10. J.L. Zambrana et al.
    Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients
    Am. J. Cardiol.
  11. M.-E. Piché et al.
    Relation of high-sensitivity c-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women
    Am. J. Cardiol.
  12. P. Maison et al.
    A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration
  13. M. Kockx et al.
    Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-□
  14. L. Mussoni et al.
    Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients
  15. C.G. Mihos et al.
    Cardiovascular effects of statins, beyond lipid-lowering properties
    Pharmacol. Res.
  16. N. Ferri et al.
    Clinical evidence of statin therapy in non-dyslipidemic disorders
    Pharmacol. Res.
  17. C.A. Dujovne et al.
    Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patient
    Am. J. Cardiol.
  18. K. Kotani et al.
    Tibolone decreases lipoprotein(a) levels in postmenopausal women: a systematic review and meta-analysis of 12 studies with 1009 patients
  19. M. Banach et al.
    Time for new indications for statins?
    Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res.
  20. J. Davignon
    Pleiotropic effects of pitavastatin
    Br. J. Clin. Pharmacol.
  21. N. Katsiki et al.
    Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels
    J. Hypertens.
  22. A. Sahebkar et al.
    Association between statin use and plasma d-dimer levels. A systematic review and meta-analysis of randomised controlled trials
    Thromb. Haemost.
  23. A. Undas et al.
    Anticoagulant effects of statins and their clinical implications
    Thromb. Haemost.
  24. A. Squizzato et al.
    Statins, fibrates, and venous thromboembolism: a meta-analysis
    Eur. Heart J.
  25. M. Elisaf
    Effects of fibrates on serum metabolic parameters
    Curr. Med. Res. Opin.
  26. N. Katsiki et al.
    The role of fibrate treatment in dyslipidemia: an overview
    Curr. Pharm. Des.
  27. V. Pasceri et al.
    Modulation of c-reactive protein–mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs
  28. B. Staels et al.
    Activation of human aortic smooth-muscle cells is inhibited by pparα but not by pparα activators
  29. C. Serban et al.
    A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations
    Sci. Rep.
  30. N.J. Stone et al.
    ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of cardiology/american heart association task force on practice guidelines
  31. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary…
    P.M.D. Chruściel et al.
    Statins and fibrates: should they be recommended?
  32. D. Moher et al.
    Preferred reporting items for systematic reviews and meta-analyses: the prisma statement
  33. S. Green, Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated march 2011]. The Cochrane…
    M. Borenstein, L. Hedges, J. Higgins, H. Rothstein. Comprehensive meta-analysis version 2. Englewood, NJ: Biostat, 104,…
  34. S.P. Hozo et al.
    Estimating the mean and variance from the median, range, and the size of a sample
    BMC Med. Res. Methodol.